New Summit data could slow US approval plans for PD-1/VEGF drug
BioPharma Dive   3 days ago
Read Full Story
New Summit data could slow US approval plans for PD-1/VEGF drug  BioPharma DiveSummit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.  Barron'sSummit shows mixed results from key study of lung cancer...